Effect of insulin-like growth factor I (IGF-I) administration on the healing of colonic anastomoses in rats

Abstract

Treatment of colon-operated rats with IGF-I increased the postoperative body weight and stimulates the collagen deposition of left colonic anastomoses, whereas the anastomotic strength may be unaffected by IGF-I treatment.

Stable Gastric Pentadecapeptide BPC 157 in Trials for Inflammatory Bowel Disease (PL-10, PLD-116, PL14736, Pliva, Croatia) Heals Ileoileal Anastomosis in the Rat

“…In contrast to the effects of pentadecapeptide BPC 157, 6,7,[10][11][12][13][14][15][16][17]25,26 other agents' effects appear to have many pitfalls: skin wound healing not accompanied with intestinal anastomosis healing, 40,41 intestinal anastomosis impaired with adhesion-preventing effect, 1 the collagen deposition of anastomoses without the anastomotic strength (IGF-I treatment), 42 or peptides (i.e., EGF, FGF, CSF, TGF-beta, CGRP, GH) needing local, subserosal application into the perianastomotic area, 43,44 and special application system [45][46] as well as carrier. 47 Clearly, huge stability, i.e., stable in human gastric juice more than 24 h, 18 and use without carrier 6,7,[10][11][12][13][14][15][16][17]25,26 (otherwise, peptide+carrier(s)−complex bears considerable methodological/activity dilemmas), 19,20 prominent Fig.…”

The Effect of Insulin-Like Growth Factor I on Healing of Colonic Anastomoses in Cortisone-Treated Rats

“…On the other hand, IGF-I is an anabolic agent that plays an important role in the metabolism of protein and fat, increases cell proliferation, and mediates body weight. In an experimental study on rats undergoing colonic anastomoses, Petersen et al 20 noticed that the exogenous administration of IGF-I resulted in an increase of the median body weight up to 5 percent. Similarly, in our study, the anabolic effects of IGF-I resulted in a significant increase of the median body weight in the IGF-I group compared with the control group.…”

Gastric Pentadecapeptide BPC 157 and Short Bowel Syndrome in Rats

“…It is possible that improved anastomosis healing [1,2] in rats with massive resection of small intestine may additionally improve with appropriate treatment by standard peptide growth factors [3][4][5][6][7][8][9][10][11][12][13][14][15][16]. Postsurgically, additional therapeutic success with improved anastomosis healing [1,2] will comprise constant weight regain, improved adaptation (e.g., in whole wall), and more appropriate application route (e.g., parenteral or peroral).…”

“…This could be important, as standard peptide growth factors sometimes have not even been tested for healing of small intestine anastomosis, as is the case for epidermal growth factor (EGF) [3,10]. Also, standard peptide growth factors do not induce weight gain [9][10][11][12][13][14][15][16] and might only decrease (but not eliminate) weight loss [9][10][11][12][13][14][15][16]. Additional adaptive intestine increase produced by standard peptide growth factors was exhibited in one layer, but not in others [9][10][11][12][13][14][15][16], unlike after common adaptive theory [3].…”

“…In addition, BPC 157 generally improved intestinal adaptation as a result of its adaptive effects, i.e., on villus height, crypt depth, and muscle thickness [and inner (circular) and/or outer (longitudinal) muscular layer], which particularly deserves to be substantiated to avoid the current methodological pitfalls inherent to all standard peptide factor intestinal adaptation studies that investigated postsurgical adaptation of some (but not all) intestinal layers without reference to normal rat intestinal layers [3][4][5][9][10][11][12][13][14][15][16]. To resolve this problem, one has to determine the range of initial increase from preoperative level, the relation between normal and adapted tissue, and the variation of the whole wall so that the rate, extent, and significance of subsequent adaptive increase of each layer postsurgically can be carefully determined.…”